Cocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
20 mai 2019 08h05 HE
|
Cocrystal Pharma, Inc.
- Humanity & Health Research Centre conducting differentiated Phase 2a study evaluating CC-31244 for the ultra-short treatment of hepatitis C (HepC) - Asia market represents one of the largest...
Cocrystal Pharma Announces Clinical Trial Agreement for Investigator-Initiated Phase 2a Study in Hong Kong of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
08 oct. 2018 08h00 HE
|
Cocrystal Pharma, Inc.
- Humanity & Health Research Centre to conduct Phase 2a study evaluating CC-31244 for the treatment of hepatitis C - Asia market represents one of the largest hepatitis C virus carrier...